Edition:
United Kingdom

Teva Pharmaceutical Industries Ltd (TEVA.N)

TEVA.N on New York Stock Exchange

16.95USD
6:32pm GMT
Change (% chg)

$0.04 (+0.24%)
Prev Close
$16.91
Open
$16.87
Day's High
$17.02
Day's Low
$16.69
Volume
1,067,267
Avg. Vol
2,152,393
52-wk High
$25.96
52-wk Low
$14.59

Chart for

About

Teva Pharmaceutical Industries Limited is a pharmaceutical company. The Company is engaged in developing, producing and marketing generic medicines and a portfolio of specialty medicines. The Company operates through two segments: Generic medicines and Specialty medicines. The Company develops, manufactures and sells generic... (more)

Overall

Beta: 0.58
Market Cap(Mil.): $18,714.96
Shares Outstanding(Mil.): 1,014.36
Dividend: 0.09
Yield (%): 6.93

Financials

  TEVA.N Industry Sector
P/E (TTM): -- 29.30 32.54
EPS (TTM): -6.03 -- --
ROI: -10.61 14.23 13.82
ROE: -24.14 15.46 15.25

U.S. settles with Teva over keeping generic drugs off market

WASHINGTON The U.S. government has reached a settlement with Teva Pharmaceuticals Industries Ltd over charges that its agreements with rivals impeded consumer access to lower-priced generic drugs.

20 Feb 2019

UPDATE 2-U.S. settles with Teva over keeping generic drugs off market

WASHINGTON, Feb 19 The U.S. government has reached a settlement with Teva Pharmaceuticals Industries Ltd over charges that its agreements with rivals impeded consumer access to lower-priced generic drugs.

20 Feb 2019

Teva expects sales injection from U.S. EpiPen market

TEL AVIV Teva Pharmaceutical Industries expects its generic version of Mylan's EpiPen to claim about 25 percent of the U.S. market by the end of the year, CEO Kare Schultz said on Tuesday, as the company closes in on a return to growth in 2020.

19 Feb 2019

UPDATE 2-Teva expects sales injection from U.S. EpiPen market

* Says will start supplying children's version within 3-4 months (Adds CEO comments, background, share price)

19 Feb 2019

Teva Pharm expects about 25 pct of EpiPen market by year end

TEL AVIV, Feb 19 Teva Pharmaceutical Industries expects its generic version of Mylan's EpiPen to have about 25 percent of the U.S. market by the end of 2019, Chief Executive Kare Schultz said on Tuesday.

19 Feb 2019

Teva Pharm sees weaker than expected 2019, shares tumble

TEL AVIV/NEW YORK Teva Pharmaceutical Industries forecast lower revenue and profit for 2019 on Wednesday, missing analysts' expectations, as it faces generic competition for two key branded drugs. | Video

13 Feb 2019

Teva CEO: 'Content' with 2/3 access of payers for migraine drug Ajovy

TEL AVIV/NEW YORK Teva Pharmaceutical Industries is "content" with having its new migraine drug Ajovy covered by nearly two-thirds of payers in the United States, Chief Executive Kare Schultz told Reuters on Wednesday.

13 Feb 2019

UPDATE 2-Teva Pharm sees weaker than expected 2019, shares tumble

* CEO says content with level of payer access for migraine drug

13 Feb 2019

Teva CEO: "Content" with 2/3 access of payers for migraine drug Ajovy

TEL AVIV/NEW YORK, Feb 13 Teva Pharmaceutical Industries is "content" with having its new migraine drug Ajovy covered by nearly two-thirds of payers in the United States, Chief Executive Kare Schultz told Reuters on Wednesday.

13 Feb 2019

Teva Pharm Q4 profit falls, sees weaker than expected 2019

TEL AVIV, Feb 13 Israel's heavily indebted Teva Pharmaceutical Industries reported a slightly larger-than-expected drop in fourth-quarter profit on Wednesday and forecast a weaker-than-expected 2019.

13 Feb 2019

Earnings vs. Estimates